Filaman

Filaman is a pre-clinical stage biotechnology company dedicated to the development of novel therapeutics targeting the filamin family of proteins. Founded by pioneers in cytoskeleton research, the company focuses on Filamin A (FLNA), a scaffolding protein that regulates cell shape, movement, and signaling. Filaman's lead programs utilize small molecule inhibitors to disrupt the interaction between filamin A and its binding partners, with the goal of preventing cancer cell migration and metastasis. Additionally, the company explores the role of filamin mutations in neurological and cardiovascular disorders. By leveraging its deep expertise in actin-binding proteins, Filaman aims to address significant unmet needs in oncology and rare genetic diseases.